CCL2 and ovarian adenocarcinoma: There was no evidence of any mutations in the CCL2 gene in 94 primary ovarian adenocarcinomas, demonstrating that CCL2 is not inactivated by somatic mutations, nor is downregulation of its expression the result of mutation in the coding or adjacent flanking sequences.